Eli Lilly struck a licensing and research agreement with ABL Bio worth up to $2.6 billion to develop therapeutics using the Grabody‑B blood‑brain barrier (BBB) penetration platform. ABL will receive a $40 million upfront payment and up to $2.56 billion in milestones plus tiered royalties, combining Lilly’s development scale with ABL’s BBB shuttle technology. Grabody‑B is designed to ferry therapeutic payloads across the BBB to address CNS disorders, a major challenge in neurology. The deal signals Big Pharma’s continued investment in delivery technologies to expand CNS addressable targets and complements recent brain‑shuttle partnerships across the industry. The agreement positions Lilly to accelerate CNS programs that require reliable brain exposure and highlights the strategic premium on delivery platforms that can unlock previously intractable indications.